drugset / Trial / NCT04349592

Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19

NCT04349592 ↗

Completed 456 enrolled Hamad Medical Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.

Timeline

Start
2020-04-14
Primary completion
2020-08-14
Completion
2020-08-30

Outcome

Missed primary endpoint

paper Day six ITT analysis found no difference (p = 0·821) in groups' proportions achieving virologic cure: HC+AZ 16/152 (10·5%), HC 19/149 (12·8%), placebo 18/147 (12·2%). PMID 33251500 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 250 mg Oral
Subject Hydroxychloroquine Small molecule 200 mg Oral

Indications